Intraductal papillary mucinous neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Intraductal papillary mucinous neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Secretin Synthetic Human and Endoscopic Aspiration Techniques for Analyzing Pancreatic Cancer in Patients with Intraductal Papillary Mucinous Neoplasia https://clinicaltrials.eu/trial/study-comparing-secretin-synthetic-human-and-endoscopic-aspiration-techniques-for-analyzing-pancreatic-cancer-in-patients-with-intraductal-papillary-mucinous-neoplasia/ Wed, 29 Apr 2026 15:02:53 +0000 https://clinicaltrials.eu/trial/study-comparing-secretin-synthetic-human-and-endoscopic-aspiration-techniques-for-analyzing-pancreatic-cancer-in-patients-with-intraductal-papillary-mucinous-neoplasia/ This clinical trial is focused on studying two conditions related to the pancreas: pancreatic cancer and intraductal papillary mucinous neoplasia (IPMN). The study will use a treatment called Chirhostim, which contains a substance known as secretin synthetic human. Secretin is a protein that helps stimulate the pancreas, and in this study, it will be used to help collect samples from the pancreas for analysis.

The purpose of the study is to compare two methods of collecting samples from the pancreas to detect specific genetic changes, known as mutations, in the genes GNAS and KRAS. These mutations can be important in understanding the nature of pancreatic conditions. The two methods being compared are called ADPJ-secr and EUS-FNA. ADPJ-secr involves collecting pancreatic juice after stimulating the pancreas with secretin, while EUS-FNA involves using a needle to collect samples directly from the pancreas with the help of an ultrasound.

Participants in the study will undergo both procedures to see which method is more effective at detecting these mutations. The study will also look at other factors, such as the concentration of DNA in the samples and the presence of other mutations like Tp53. The study aims to provide valuable information that could improve the diagnosis and treatment of pancreatic conditions. Participants will be monitored for any side effects from the procedures, and the study will continue until the end of 2026.

]]>